ReviewCurrent opinion in allergy and clinical immunology2014
T helper subsets in allergic eye disease.
Review in Current opinion in allergy and clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Reduced Levels of Resolvin D1 and Thrombospondin-1 in Vernal Keratoconjunctivitis.Journal of clinical practice and research · 2026Article
- γδ T Cells and Allergic Diseases.Clinical reviews in allergy & immunology · 2023Review
- Blocking Th2 Signaling Pathway Alleviates the Clinical Symptoms and Inflammation in Allergic Conjunctivitis.Investigative ophthalmology & visual science · 2023Article
- Conjunctival infiltrates and cytokines in an experimental immune-mediated blepharoconjunctivitis rat model.Frontiers in medicine · 2023Article
- Immune regulation of the ocular surface.Experimental eye research · 2022Review
- Molecular Characteristics and Distribution of Adult Human Corneal Immune Cell Types.Frontiers in immunology · 2022Article
- Increased Expression of TLR4 in Circulating CD4+T Cells in Patients with Allergic Conjunctivitis and In Vitro Attenuation of Th2 Inflammatory Response by Alpha-MSH.International journal of molecular sciences · 2020Article
- Potential Biomarkers for Allergic Conjunctival Diseases.Eye & contact lens · 2020Review
- Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development.Pharmaceutical research · 2019Review
- Unlike Th1/Th17 cells, Th2/Th9 cells selectively migrate to the limbus/conjunctiva and initiate an eosinophilic infiltration process.Experimental eye research · 2018Article
- Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study.BMJ open · 2017Article
- Review
- Secondary allergic T cell responses are regulated by dendritic cell-derived thrombospondin-1 in the setting of allergic eye disease.Journal of leukocyte biology · 2016Article
- Linking immune responses with fibrosis in allergic eye disease.Current opinion in allergy and clinical immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewOcular allergy is an IgE-mediated disease that results in inflammation of the conjunctiva and, in more severe cases, the cornea. This is driven by an immediate hypersensitivity response via mast cells, followed by a late phase response mediated by eosinophils both of which are indeed dependent on T helper (Th) lymphocyte activity. Here, we provide an update on Th subsets [Th1, Th2, Th17, and T regulatory (Treg)] and their relevance in ocular allergy. RECENT
findingsRecent evidence in ocular allergy points to an involvement of other Th subsets, in addition to Th2. However, how these subsets are activated and their role in mediating the different clinical forms is poorly understood. Novel mouse models may facilitate addressing such unknowns, and future challenges will involve how to translate such findings into more effective and 'patho-specific' treatments. SUMMARY: Ocular allergy, especially in severe forms, involves subsets other than Th2. Th1 cells have been detected in mild and severe forms, and recent evidence points to a possible role for IL-17 in severe disease. Tregs, on the other hand, dampen pathogenic Th cell function and allergy immunotherapy is associated with Treg augmentation in disease management. Further understanding of Th biology is warranted and may lead to better therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.